[1] |
Devarbhavi H, Asrani SK, Arab JP, et al. Global burden of liver disease: 2023 update[J]. J Hepatol,2023,79(2):516-537.
|
[2] |
Ghyselinck NB, Duester G. Retinoic acid signaling pathways[J]. Development,2019,146(13):dev167502.
|
[3] |
Melis M, Tang XH, Trasino SE, et al. Retinoids in the pathogenesis and treatment of liver diseases[J]. Nutrients,2022,14(7):1456.
|
[4] |
Li B, Cai SY, Boyer JL. The role of the retinoid receptor, RAR/RXR heterodimer, in liver physiology[J]. Biochim Biophys Acta Mol Basis Dis,2021,1867(5):166085.
|
[5] |
Li Y, Wong K, Walsh K, et al. Retinoic acid receptor β stimulates hepatic induction of fibroblast growth factor 21 to promote fatty acid oxidation and control whole-body energy homeostasis in mice[J]. J Biol Chem,2013,288(15):10490-10504.
|
[6] |
Trasino SE, Tang XH, Jessurun J, et al. Retinoic acid receptor β2 agonists restore glycaemic control in diabetes and reduce steatosis[J]. Diabetes Obes Metab,2016,18(2):142-151.
|
[7] |
Melis M, Tang XH, Trasino SE, et al. Effects of AM80 compared to AC261066 in a high fat diet mouse model of liver disease[J]. PLoS One,2019,14(1):e0211071.
|
[8] |
Tang XH, Melis M, Lu C, et al. A retinoic acid receptor β2 agonist attenuates transcriptome and metabolome changes underlying nonalcohol-associated fatty liver disease[J]. J Biol Chem,2021,297(6):101331.
|
[9] |
Byrne CD, Targher G. What’s new in NAFLD pathogenesis, biomarkers and treatment?[J]. Nat Rev Gastroenterol Hepatol, 2020,17(2):70-71.
|
[10] |
Sanyal AJ. Past, present and future perspectives in nonalcoholic fatty liver disease[J]. Nat Rev Gastroenterol Hepatol,2019,16(6):377-386.
|
[11] |
Parlati L, Régnier M, Guillou H, et al. New targets for NAFLD[J]. JHEP Rep,2021,3(6):100346.
|
[12] |
Friedman SL, Neuschwander-Tetri BA, Rinella M, et al. Mechanisms of NAFLD development and therapeutic strategies[J]. Nat Med,2018,24(7):908-922.
|
[13] |
Tilg H, Adolph TE, Dudek M, et al. Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity[J]. Nat Metab,2021,3(12):1596-1607.
|
[14] |
Blaner WS, O’Byrne SM, Wongsiriroj N, et al. Hepatic stellate cell lipid droplets: A specialized lipid droplet for retinoid storage[J]. Biochim Biophys Acta,2009,1791(6):467-473.
|
[15] |
Haaker MW, Vaandrager AB, Helms JB. Retinoids in health and disease: A role for hepatic stellate cells in affecting retinoid levels[J]. Biochim Biophys Acta Mol Cell Biol Lipids,2020,1865(6):158674.
|
[16] |
Geng C, Xu H, Zhang Y, et al. Retinoic acid ameliorates high-fat diet-induced liver steatosis through sirt1[J]. Sci China Life Sci,2017,60(11):1234-1241.
|
[17] |
Saeed A, Dullaart RPF, Schreuder TCMA, et al. Disturbed vitamin A metabolism in non-alcoholic fatty liver disease (NAFLD)[J]. Nutrients,2017,10(1):29.
|
[18] |
Yang D, Vuckovic MG, Smullin CP, et al. Modest decreases in endogenous all-trans-retinoic acid produced by a mouse rdh10 heterozygote provoke major abnormalities in adipogenesis and lipid metabolism[J]. Diabetes,2018,67(4):662-673.
|
[19] |
Sharpton SR, Schnabl B, Knight R, et al. Current concepts, opportunities, and challenges of gut microbiome-based personalized medicine in nonalcoholic fatty liver disease[J]. Cell Metab,2021, 33(1):21-32.
|
[20] |
Kolodziejczyk AA, Zheng D, Shibolet O, et al. The role of the microbiome in NAFLD and NASH[J]. EMBO Mol Med,2019, 11(2):e9302.
|
[21] |
Nicoletti A, Ponziani FR, Biolato M, et al. Intestinal permeability in the pathogenesis of liver damage: From non-alcoholic fatty liver disease to liver transplantation[J]. World J Gastroenterol,2019, 25(33):4814-4834.
|
[22] |
Li Y, Gao Y, Cui T, et al. Retinoic acid facilitates toll-like receptor 4 expression to improve intestinal barrier function through retinoic acid receptor beta[J]. Cell Physiol Biochem,2017,42(4):1390-1406.
|
[23] |
Dunn W, Shah VH. Pathogenesis of alcoholic liver disease[J]. Clin Liver Dis,2016,20(3):445-456.
|
[24] |
Ferdouse A, Agrawal RR, Gao MA, et al. Alcohol induced hepatic retinoid depletion is associated with the induction of multiple retinoid catabolizing cytochrome P450 enzymes[J]. PLoS One,2022, 17(1):e0261675.
|
[25] |
Melis M, Tang XH, Attarwala N, et al. A retinoic acid receptor β2 agonist protects against alcohol liver disease and modulates hepatic expression of canonical retinoid metabolism genes[J]. Biofactors, 2022,48(2):469-480.
|
[26] |
Kane MA, Folias AE, Wang C, et al. Ethanol elevates physiological all- trans -retinoic acid levels in select loci through altering retinoid metabolism in multiple loci: a potential mechanism of ethanol toxicity[J]. FASEB J,2010,24(3):823-832.
|
[27] |
Ganne-Carrié N, Nahon P. Hepatocellular carcinoma in the setting of alcohol-related liver disease[J]. J Hepatol,2019,70(2):284-293.
|
[28] |
Diesinger T, Buko V, Lautwein A, et al. Drug targeting CYP2E1 for the treatment of early-stage alcoholic steatohepatitis[J]. PLoS One,2020,15(7):e0235990.
|
[29] |
Tang XH, Melis M, Mai K, et al. Fenretinide improves intestinal barrier function and mitigates alcohol liver disease[J]. Front Pharmacol,2021,12:630557.
|
[30] |
Yeom S, Kim SS, Jeong H, et al. Hepatitis B virus X protein activates E3 ubiquitin ligase Siah-1 to control virus propagation via a negative feedback loop[J]. J Gen Virol,2017,98(7):1774-1784.
|
[31] |
Han J, Jang KL. All-trans retinoic acid inhibits hepatitis B virus replication by downregulating HBx levels via Siah-1-mediated proteasomal degradation[J]. Viruses,2023,15(7):1456.
|
[32] |
Kwak J, Shim JH, Tiwari I, et al. Hepatitis C virus core protein inhibits E6AP expression via DNA methylation to escape from ubiquitin-dependent proteasomal degradation[J]. Cancer Lett,2016,380(1):59-68.
|
[33] |
Chen C, Pan D, Deng AM, et al. DNA methyltransferases 1 and 3B are required for hepatitis C virus infection in cell culture[J]. Virology,2013,441(1):57-65.
|
[34] |
Lee HK, Yoon H, Jang KL. All-trans retinoic acid inhibits HCV replication by downregulating core levels via E6AP-mediated proteasomal degradation[J]. Biochem Biophys Res Commun, 2022,594:15-21.
|
[35] |
Nagel M, Labenz C, Dobbermann H, et al. Suppressed serological vitamin A in patients with liver cirrhosis is associated with impaired liver function and clinical detoriation[J]. Eur J Gastroenterol Hepatol,2022,34(10):1053-1059.
|
[36] |
Simbrunner B, Semmler G, Stadlmann A, et al. Vitamin A levels reflect disease severity and portal hypertension in patients with cirrhosis[J]. Hepatol Int,2020,14(6):1093-1103.
|
[37] |
Kisseleva T, Brenner D. Molecular and cellular mechanisms of liver fibrosis and its regression[J]. Nat Rev Gastroenterol Hepatol,2021,18(3):151-166.
|
[38] |
Trasino SE, Tang XH, Jessurun J, et al. A retinoic acid receptor β2 agonist reduces hepatic stellate cell activation in nonalcoholic fatty liver disease[J]. J Mol Med (Berl),2016,94(10):1143-1151.
|
[39] |
Radaeva S, Wang L, Radaev S, et al. Retinoic acid signaling sensitizes hepatic stellate cells to NK cell killing via upregulation of NK cell activating ligand RAE1[J]. Am J Physiol Gastrointest Liver Physiol,2007,293(4):G809-G816.
|
[40] |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2021,71(3):209-249.
|
[41] |
Younossi Z, Stepanova M, Ong JP, et al. Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates[J]. Clin Gastroenterol Hepatol,2019,17(4):748-755. e3.
|
[42] |
Datfar T, Doulberis M, Papaefthymiou A, et al. Viral hepatitis and hepatocellular carcinoma: state of the art[J]. Pathogens, 2021,10(11):1366.
|
[43] |
Chen Z, Tian R, She Z, et al. Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease[J]. Free Radic Biol Med,2020,152:116-141.
|
[44] |
Irshad M, Gupta P, Irshad K. Immunopathogenesis of liver injury during hepatitis C virus infection[J]. Viral Immunol,2019,32(3):112- 120.
|
[45] |
Cortes E, Lachowski D, Rice A, et al. Retinoic acid receptor-βis downregulated in hepatocellular carcinoma and cirrhosis and its expression inhibits myosin-driven activation and durotaxis in hepatic stellate cells[J]. Hepatology,2019 69(2):785-802.
|
[46] |
Liao XH, Zhang AL, Zheng M, et al. Chemical or genetic Pin1 inhibition exerts potent anticancer activity against hepatocellular carcinoma by blocking multiple cancer-driving pathways[J]. Sci Rep,2017,7(1):43639.
|